CR20190400A - Formulaciones de anticuerpo monoclonal anti-vrs - Google Patents
Formulaciones de anticuerpo monoclonal anti-vrsInfo
- Publication number
- CR20190400A CR20190400A CR20190400A CR20190400A CR20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A
- Authority
- CR
- Costa Rica
- Prior art keywords
- monoclonal antibody
- antibody formulation
- rsv monoclonal
- formulation
- present
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona una formulación que comprende: (i) un anticuerpo monoclonal anti-VRS; y (ii) un excipiente iónico; en donde el anticuerpo monoclonal está presente a una concentración de aproximadamente 50 mg/ml o más y el excipiente iónico está presente a una concentración de entre 50 y 150 mM y la formulación tiene un pH de aproximadamente 5.5 a aproximadamente 7.5.The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762465379P | 2017-03-01 | 2017-03-01 | |
PCT/US2018/020264 WO2018160722A1 (en) | 2017-03-01 | 2018-02-28 | Anti-rsv monoclonal antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190400A true CR20190400A (es) | 2019-12-03 |
Family
ID=61903153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190400A CR20190400A (es) | 2017-03-01 | 2018-02-28 | Formulaciones de anticuerpo monoclonal anti-vrs |
Country Status (23)
Country | Link |
---|---|
US (4) | US10774133B2 (es) |
EP (1) | EP3589648A4 (es) |
JP (2) | JP7046088B2 (es) |
KR (2) | KR102668158B1 (es) |
CN (3) | CN110418803B (es) |
AR (1) | AR111083A1 (es) |
AU (2) | AU2018227502B2 (es) |
BR (1) | BR112019017755A2 (es) |
CA (1) | CA3051864A1 (es) |
CL (1) | CL2019002478A1 (es) |
CO (1) | CO2019009034A2 (es) |
CR (1) | CR20190400A (es) |
EA (1) | EA201991701A1 (es) |
EC (1) | ECSP19062769A (es) |
GB (1) | GB2564175B (es) |
IL (2) | IL312499A (es) |
MX (1) | MX2019010408A (es) |
PH (1) | PH12019501979A1 (es) |
SG (1) | SG11201906853QA (es) |
TW (2) | TWI761453B (es) |
UA (1) | UA128450C2 (es) |
WO (1) | WO2018160722A1 (es) |
ZA (1) | ZA202006797B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE048855T2 (hu) | 2014-01-15 | 2020-08-28 | Medimmune Llc | RSV-re specifikus ellenanyagok és azok funkcionális részei |
EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED AMINO ACID AND SUGAR REPORTS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3589318A1 (en) * | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
EP3867271A4 (en) | 2018-10-18 | 2022-08-03 | Merck Sharp & Dohme Corp. | ANTI-RSV ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
CN113993884A (zh) * | 2019-04-18 | 2022-01-28 | 弗劳恩霍夫应用研究促进协会 | 抑制呼吸道合胞病毒感染的生物及合成分子 |
US12024553B2 (en) | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Rq生物科技有限公司 | 抗體 |
WO2024016842A1 (zh) * | 2022-07-22 | 2024-01-25 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
WO2024120517A1 (zh) * | 2022-12-08 | 2024-06-13 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
EP0851924A1 (en) | 1995-09-18 | 1998-07-08 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
AU2002363339B2 (en) * | 2001-11-08 | 2008-02-07 | Abbvie Biotechnology Ltd | Stable liquid pharmaceutical formulation of IGG antibodies |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
AU2013201261B2 (en) * | 2002-06-14 | 2016-06-23 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
EP2639242A3 (en) * | 2006-03-06 | 2013-10-16 | MedImmune, Inc. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
EP2346990B1 (en) | 2008-11-05 | 2016-01-06 | Merck Sharp & Dohme Corp. | Live, attentuated respiratory syncytial virus |
WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
JP5734988B2 (ja) | 2009-10-06 | 2015-06-17 | メディミューン リミテド | Rsv特異的結合分子 |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
CL2011003002A1 (es) | 2011-11-25 | 2012-05-25 | Univ Pontificia Catolica Chile | Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento. |
CA3123252C (en) * | 2012-03-26 | 2023-08-22 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
CN105073196B (zh) | 2013-02-01 | 2020-04-07 | 米迪缪尼有限公司 | 呼吸道合胞病毒f蛋白表位 |
HUE048855T2 (hu) | 2014-01-15 | 2020-08-28 | Medimmune Llc | RSV-re specifikus ellenanyagok és azok funkcionális részei |
WO2016059512A1 (en) * | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
KR102638978B1 (ko) | 2015-07-07 | 2024-02-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3589318A1 (en) * | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
-
2018
- 2018-02-13 TW TW107105368A patent/TWI761453B/zh active
- 2018-02-13 TW TW111113045A patent/TW202228779A/zh unknown
- 2018-02-23 GB GB1802974.4A patent/GB2564175B/en active Active
- 2018-02-26 AR ARP180100448A patent/AR111083A1/es unknown
- 2018-02-28 KR KR1020227003517A patent/KR102668158B1/ko active IP Right Grant
- 2018-02-28 CN CN201880014929.6A patent/CN110418803B/zh active Active
- 2018-02-28 IL IL312499A patent/IL312499A/en unknown
- 2018-02-28 AU AU2018227502A patent/AU2018227502B2/en active Active
- 2018-02-28 CN CN202410036839.4A patent/CN117982637A/zh active Pending
- 2018-02-28 WO PCT/US2018/020264 patent/WO2018160722A1/en unknown
- 2018-02-28 SG SG11201906853QA patent/SG11201906853QA/en unknown
- 2018-02-28 CR CR20190400A patent/CR20190400A/es unknown
- 2018-02-28 CA CA3051864A patent/CA3051864A1/en active Pending
- 2018-02-28 IL IL268202A patent/IL268202B2/en unknown
- 2018-02-28 EP EP18761614.9A patent/EP3589648A4/en active Pending
- 2018-02-28 US US15/907,876 patent/US10774133B2/en active Active
- 2018-02-28 KR KR1020197025250A patent/KR102359181B1/ko active IP Right Grant
- 2018-02-28 MX MX2019010408A patent/MX2019010408A/es unknown
- 2018-02-28 BR BR112019017755A patent/BR112019017755A2/pt not_active Application Discontinuation
- 2018-02-28 CN CN202210988780.XA patent/CN116059343A/zh active Pending
- 2018-02-28 JP JP2019547310A patent/JP7046088B2/ja active Active
- 2018-02-28 EA EA201991701A patent/EA201991701A1/ru unknown
- 2018-02-28 UA UAA201908966A patent/UA128450C2/uk unknown
-
2019
- 2019-08-21 CO CONC2019/0009034A patent/CO2019009034A2/es unknown
- 2019-08-28 CL CL2019002478A patent/CL2019002478A1/es unknown
- 2019-08-29 PH PH12019501979A patent/PH12019501979A1/en unknown
- 2019-08-29 EC ECSENADI201962769A patent/ECSP19062769A/es unknown
-
2020
- 2020-07-13 US US16/927,169 patent/US11667698B2/en active Active
- 2020-10-30 ZA ZA2020/06797A patent/ZA202006797B/en unknown
-
2021
- 2021-06-18 US US17/351,348 patent/US11286294B2/en active Active
-
2022
- 2022-03-22 JP JP2022045862A patent/JP7446356B2/ja active Active
- 2022-11-04 AU AU2022263564A patent/AU2022263564A1/en active Pending
-
2023
- 2023-04-28 US US18/309,475 patent/US20230399383A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190400A (es) | Formulaciones de anticuerpo monoclonal anti-vrs | |
MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
CO2018003134A2 (es) | Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante | |
GT201100181A (es) | "inhibidores de proteina cinasa" | |
PE20191796A1 (es) | Composicion farmaceutica de clorhidrato de s-ketamina | |
CL2012001966A1 (es) | Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis. | |
BR112021017890A2 (pt) | Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana | |
PE20191242A1 (es) | Formulaciones de anticuerpo y metodos | |
ECSP088962A (es) | Nuevos herbicidas | |
EA201991769A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК | |
UY39135A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
PE20191476A1 (es) | Nueva formulacion estable de anticuerpos anti-fxia | |
MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. |